格隆汇2月27日丨美因基因(06667.HK)发布公告，该公司的股份将于今天(27/2/2026)上午九时正起恢复 买卖。 ...

美因基因(06667)发布公告，公司已达成所有复牌指引。公司已申请于2026年2月27日上午9时正起恢复 公司股份于联交所买卖。 ...

智通财经APP讯，美因基因(06667)发布公告，公司已达成所有复牌指引。公司已申请于2026年2月27日 上午9时正起恢复公司股份于联交所买卖。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號： 6667） 達成所有復牌指引 及 恢復買賣 本公司的財務顧問 滙生國際資本有限公司 緒言 本公告乃由美因基因有限公司（「本公司」），連同其附屬公司統稱「本集團」）根據香港聯 合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條以及香港法 例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上市規則）而作出。 –1– 茲提述本公司日期為2025年4月1日、2025年4月22日、2025年4月30日、2025年5月5日、 2025年5月30日、2025年6月30日、2025年8月29日、2025年9月30日、2025年11月10日、 2025年12月31日、2026年1月12日、2026年1月30日、2026年2月4日及2026年2月9日（「該等 公告」 ...

Genetic Testing and Diagnostic Solutions - As of June 30, 2025, the company has conducted over 24 million genetic tests, making it the largest consumer genetic testing platform in China by cumulative testing volume [11]. - The company has developed 114 commercialized testing solutions for consumer genetic testing and cancer screening, with 94 of these being independently developed [12]. - The company offers a range of services, including brain health assessment, nutritional absorption capability assessment, and comprehensive cancer risk assessment [12]. - The company is developing eight in vitro diagnostic (IVD) pipeline products, including three consumer-grade genetic testing kits for assessing risks of various diseases, with regulatory approval expected by 2025 [13]. - The ApoE genetic testing kit, which assesses Alzheimer's disease risk, utilizes a blood nucleic acid non-extraction technology, reducing testing costs and time [16]. - The folate metabolism assessment kit provides guidance for pregnant women to prevent neonatal defects and assess risks of cardiovascular diseases, with regulatory approval expected by 2025 [17]. - The Alzheimer's disease screening kit is based on plasma miRNA biomarkers, with clinical validation involving at least 1,500 samples and collaboration with multiple hospitals [18]. - The colorectal cancer screening kit is based on plasma DNA methylation biomarkers, with preliminary screening completed and collaboration with three hospitals for clinical validation [20]. - The gastric cancer screening kit also utilizes plasma DNA methylation biomarkers, with similar development and validation processes as the colorectal cancer kit [24]. - The BRCA1/BRCA2 genetic mutation testing kit has completed formulation development and established a database of tens of thousands of mutation sites [29]. - The company anticipates developing qPCR and NGS testing kits for various diseases, with expected sensitivity and specificity greater than 90% [22]. - The qPCR kits for colorectal and gastric cancer will include three biomarkers and are expected to enter the IVD registration phase by 2027 [23][27]. - The company is focusing on diseases with high prevalence and lack of effective screening methods, aiming to expand its product offerings in the diagnostic market [13]. Financial Performance - The company achieved a revenue of RMB 81.3 million, representing a year-on-year decline of 24.2% [44]. - The net profit for the period was RMB 27.3 million, down 26.3% year-on-year, primarily due to adjustments in sales strategy and fixed costs [44]. - For the six months ended June 30, 2025, the company reported revenue of RMB 81.3 million, a decrease of 24.2% compared to RMB 107.3 million for the same period in 2024 [46]. - The gross profit for the same period was RMB 60.1 million, down 13.6% year-over-year, with a gross margin of 74.0%, an increase of 9.1 percentage points from the previous year [48]. - Net profit for the six months ended June 30, 2025, was RMB 27.3 million, representing a decline of 26.3% compared to RMB 37.0 million in 2024 [56]. - The revenue from consumer-grade genetic testing services was RMB 75.9 million, while cancer screening services generated RMB 5.3 million, with the latter showing an impressive growth of 85.7% year-over-year [46]. - Total revenue for the six months ended June 30, 2025, was RMB 812.81 million, down from RMB 1,072.91 million in the same period of 2024 [59]. - The cost of sales decreased by 43.9% from RMB 376.73 million in 2024 to RMB 211.41 million in 2025, primarily due to lower revenue [62]. - Gross profit for the six months ended June 30, 2025, was RMB 601.40 million, with a gross margin of 74.0%, compared to RMB 696.18 million and 64.9% in 2024 [63]. - Other income increased by 22.5% from RMB 34 million in 2024 to RMB 42 million in 2025, mainly due to higher interest income [66]. - Selling and distribution expenses decreased by 23.4% from RMB 136 million in 2024 to RMB 104 million in 2025, reflecting reduced sales costs [67]. Research and Development - The company has a strong internal R&D team, with approximately 65% of members holding master's degrees or higher from prestigious institutions [33]. - The company plans to enhance its R&D capabilities by recruiting more professionals and collaborating with renowned academic and medical institutions [51]. - The company aims to develop low-cost, home-testing screening products to diversify its product portfolio and strengthen its market leadership [51]. - The cancer screening market is expected to grow, with the company focusing on increasing automation in production to reduce costs and improve product sensitivity and specificity [50]. - The company is in the early development stages of diagnostic kits for lung nodules and cervical cancer screening [40]. - The company has developed a non-invasive oral swab sampler to enhance accessibility and affordability of genetic testing for various demographics [41]. - The company collaborates with leading medical experts to accelerate clinical trials and enhance product reliability [34]. Corporate Governance and Compliance - The company has maintained compliance with corporate governance codes and standards throughout the reporting period [138][139]. - The company has not adopted any new or revised Hong Kong Financial Reporting Standards that are not yet effective, indicating a stable accounting policy environment [156]. - The company has assessed the impact of the revised Hong Kong Financial Reporting Standards and found no significant effect on its financial position or performance [154]. - The company operates as a single reportable operating segment, focusing on overall business performance rather than service-based divisions [159]. - The company has maintained the classification of its liabilities as current or non-current following the adoption of the revised standards, with no changes expected [154]. - The company is preparing to apply the new and revised Hong Kong Financial Reporting Standards upon their effective date, ensuring compliance and accuracy in financial reporting [156]. Shareholder Information and Equity - As of June 30, 2025, Dr. Yu Rong holds 18,795,135 shares (8.38%) and has an additional 22,000,000 shares (9.81%) through controlled entities [120]. - Ms. Guo Meiling owns 22,273,970 shares (9.93%) through controlled entities and 4,545,000 shares (2.03%) as beneficial ownership [120]. - Ms. Lin Lin has 9,975,311 shares (4.45%) through controlled entities and 13,636,000 shares (6.08%) as beneficial ownership [120]. - The total number of shares issued by the company as of June 30, 2025, is 224,300,200 shares [126]. - The company has granted a total of 19,181,000 restricted share units to several directors as of June 30, 2025 [126]. - The ownership structure indicates significant control by key executives, with Dr. Yu Rong and Ms. Guo Meiling having substantial stakes in the company [120]. - During the reporting period, the company repurchased a total of 3,834,000 shares at a total cost of HKD 32,897,016 [130]. - The share repurchase was aimed at increasing net asset value per share and earnings per share, authorized at the 2024 annual general meeting [132]. - The company raised approximately HKD 153.4 million from its global offering, with net proceeds allocated as follows: 30% for sales and marketing, 25% for R&D, 20% for testing capabilities and production capacity, 15% for investments and acquisitions, and 10% for working capital [134][135]. - As of June 30, 2025, the actual usage of the net proceeds was HKD 130.4 million, with HKD 23.0 million remaining for investments and acquisitions expected to be utilized by December 31, 2028 [135][136]. Operational Metrics - The company’s high-throughput testing platform can process up to 50,000 samples daily, providing cost-effective gene testing solutions [42]. - The current ratio as of June 30, 2025, was 15.2, significantly higher than 5.4 in 2024 [84]. - The company’s inventory increased to RMB 5,351,000 as of June 30, 2025, compared to RMB 4,609,000 as of December 31, 2024 [143]. - The company’s total assets less current liabilities stood at RMB 649,869,000 as of June 30, 2025, compared to RMB 647,837,000 as of December 31, 2024 [143]. - The group’s trade payables as of June 30, 2025, totaled RMB 25,376,000, slightly down from RMB 25,433,000 as of December 31, 2024 [176]. - The group’s research and development costs for the six months ended June 30, 2025, were RMB 8,151,000, a decrease from RMB 9,934,000 in 2024 [166].

Core Viewpoint - The company reported a decline in both revenue and net profit for the six months ending June 30, 2025, primarily due to a strategic shift in sales approach, leading to a temporary decrease in revenue [1] Financial Performance - The company achieved a revenue of RMB 81.3 million, representing a year-on-year decrease of 24.2% [1] - The net profit for the period was RMB 27.3 million, reflecting a year-on-year decline of 26.3% [1] Strategic Partnerships - As of June 30, 2025, the company has established collaborations with healthcare institutions in over 340 cities across China, enhancing its sales and marketing network [1] - The company has partnered with several e-commerce and online healthcare platforms to expand and improve its sales and marketing network [1]

Core Viewpoint - The company reported a decline in both revenue and net profit for the six months ending June 30, 2025, primarily due to a strategic adjustment in sales, leading to a temporary decrease in revenue [1] Financial Performance - The company achieved a revenue of RMB 81.3 million, representing a year-on-year decrease of 24.2% [1] - The net profit for the period was RMB 27.3 million, reflecting a year-on-year decline of 26.3% [1] Strategic Adjustments - The decline in revenue and net profit is attributed to the company's adjustment in sales strategy, which resulted in a temporary drop in revenue [1] - Fixed costs such as labor, rent, and depreciation contributed to the reduction in net profit despite the revenue decline [1] Market Presence - As of June 30, 2025, the company collaborates with healthcare institutions in over 340 cities across China, enabling it to provide genetic testing services to a large portion of the Chinese population [1] - The company has partnered with several e-commerce and online healthcare platforms to expand and enhance its sales and marketing network [1]

Core Viewpoint - The company reported a decline in both revenue and net profit for the six months ending June 30, 2025, primarily due to a strategic adjustment in sales, leading to a temporary decrease in revenue [1] Financial Performance - The company achieved a revenue of RMB 81.3 million, representing a year-on-year decrease of 24.2% [1] - The net profit for the period was RMB 27.3 million, reflecting a year-on-year decline of 26.3% [1] Strategic Adjustments - The decline in revenue and net profit is attributed to the company's adjustment in sales strategy, which resulted in a temporary drop in revenue [1] - Fixed costs such as labor, rent, and depreciation contributed to the reduction in net profit during this period [1] Market Presence - As of June 30, 2025, the company collaborates with healthcare institutions in over 340 cities across China, enhancing its sales and marketing network [1] - The company has partnered with several e-commerce and online healthcare platforms to expand and improve its sales and marketing network [1]

Core Viewpoint - The company reported a decline in both revenue and net profit for the six months ending June 30, 2025, primarily due to adjustments in sales strategy and fixed costs impacting profitability [1] Financial Performance - The company achieved operating revenue of RMB 81.3 million, representing a year-on-year decrease of 24.2% [1] - The net profit for the period was RMB 27.3 million, reflecting a year-on-year decline of 26.3% [1] - Earnings per share attributable to ordinary equity holders of the parent company was RMB 0.13 [1] Business Operations - The company is a leading gene testing platform in China, focusing on consumer-grade gene testing services and cancer screening [1] - As of June 30, 2025, the company has conducted over 24 million gene tests [1] - The company collaborates with healthcare institutions in over 340 cities across China, enhancing its sales and marketing network to provide gene testing services to a large portion of the population [1] - Partnerships with various e-commerce and online healthcare platforms are in place to expand and improve the sales and marketing network [1]

Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 81.3 million, a decrease of 24.2% compared to RMB 107.3 million in the same period of 2024[6]. - The net profit for the same period was RMB 27.3 million, down 26.3% from RMB 37.0 million year-on-year[6]. - The gross profit was RMB 60.1 million, reflecting a 13.6% decline compared to RMB 69.6 million in the previous year[9]. - Revenue for the six months ended June 30, 2025, was RMB 81,281,000, a decrease of 24.3% compared to RMB 107,291,000 for the same period in 2024[54]. - Gross profit for the same period was RMB 60,140,000, down 13.6% from RMB 69,618,000 in 2024[54]. - Net profit for the period was RMB 27,261,000, representing a decline of 26.3% from RMB 36,969,000 in the previous year[54]. - Basic and diluted earnings per share for the period were RMB 0.13, down from RMB 0.18 in 2024[54]. Revenue Breakdown - Revenue from consumer genetic testing services was RMB 75.9 million, down 27.3% year-on-year, while revenue from cancer screening services increased by 85.7% to RMB 5.3 million[7]. - Revenue from consumer-grade genetic testing services was RMB 75,947 thousand for the six months ended June 30, 2025, down from RMB 104,419 thousand in 2024, representing a decline of 27.2%[68]. - Revenue from cancer screening services increased by 85.7% year-over-year to RMB 5.3 million, due to an expanded product offering[17]. Cost and Expenses - Sales and distribution expenses decreased by 23.4% to RMB 10.4 million from RMB 13.6 million in the previous year, primarily due to reduced revenue[23]. - The cost of services provided was RMB 21,141 thousand for the six months ended June 30, 2025, down from RMB 37,673 thousand in 2024, reflecting a decrease of 43.8%[71]. - Research and development costs amounted to RMB 8,151 thousand for the six months ended June 30, 2025, compared to RMB 9,934 thousand in 2024, indicating a reduction of 17.9%[71]. Assets and Liabilities - Cash and cash equivalents decreased by 6.3% from RMB 490.3 million as of December 31, 2024, to RMB 459.5 million as of June 30, 2025[32]. - Total assets as of June 30, 2025, were RMB 649,869,000, slightly up from RMB 647,837,000 as of December 31, 2024[56]. - Current liabilities decreased significantly to RMB 38,151,000 from RMB 90,640,000 at the end of 2024, indicating improved liquidity[55]. - Non-current liabilities increased to RMB 38,269,000 from RMB 33,157,000, reflecting changes in financing arrangements[56]. Corporate Governance and Compliance - The company has established an audit committee to provide independent opinions on financial reporting procedures, internal controls, and risk management systems[91]. - The audit committee consists of three members, ensuring compliance with the relevant listing rules and corporate governance codes[91]. - The company has adhered to strict corporate governance principles, maintaining high standards of ethics, transparency, accountability, and integrity[89]. - The interim financial results for the six months ending June 30, 2025, have been reviewed by the audit committee[91]. - The company has confirmed compliance with the standard code for securities transactions by directors during the reporting period[90]. Future Plans and Market Potential - The penetration rate of the consumer genetic testing market in China is expected to grow from 0.8% in 2020 to 11.6% by 2030, indicating significant market potential[10]. - The company plans to enhance collaboration with industry leaders to establish industry standards and accelerate market penetration[10]. - Future product development will focus on expanding cancer screening offerings, including innovative tests for esophageal, endometrial, and bladder cancers[11]. - The company aims to increase R&D investment to develop high-cost performance tumor early screening products, contributing to public health goals[11]. - The company aims to pursue selective regional expansion and acquisition opportunities to complement internal growth and enhance its product portfolio[13]. Share Repurchase and Dividends - The company repurchased a total of 3,834,000 shares during the reporting period, at a total cost of HKD 32,897,016[87]. - The company did not declare or pay any dividends during the reporting period[75]. - The repurchase was aimed at enhancing net asset value per share and earnings per share, authorized by the board at the 2024 annual general meeting[88]. - As of June 30, 2025, all repurchased shares have been canceled[88]. Audit and Investigation - An independent forensic investigation is ongoing to address audit issues and assess their impact on business operations and financial condition[49]. - The company has engaged external consultants to review its internal control systems and procedures, with findings to be reported in early 2026[52].